ConductScience.org, home
A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris
API referenceFor AI assistants

Trial · NCT01268527

Results by group160

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 160

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Summary Statistics and Primary Pairwise Comparison (Vehicle-E6201) of Area Under the Curve (AUC) for the Baseline-Corrected Thickness of the Psoriatic InfiltrateDaivonex (Calcipotriene Cream)-1449.295% Confidence Interval -1660.0 to -1238.4um.day
Summary Statistics and Primary Pairwise Comparison (Vehicle-E6201) of Area Under the Curve (AUC) for the Baseline-Corrected Thickness of the Psoriatic InfiltrateE6201 Vehicle17.095% Confidence Interval -64.3 to 98.3um.day
Summary Statistics and Primary Pairwise Comparison (Vehicle-E6201) of Area Under the Curve (AUC) for the Baseline-Corrected Thickness of the Psoriatic Infiltrate0.005% E6201 Gel-694.495% Confidence Interval -1108.0 to -280.8um.day
Summary Statistics and Primary Pairwise Comparison (Vehicle-E6201) of Area Under the Curve (AUC) for the Baseline-Corrected Thickness of the Psoriatic Infiltrate0.01% E6201 Gel-1102.895% Confidence Interval -1351.8 to -853.8um.day
Summary Statistics and Primary Pairwise Comparison (Vehicle-E6201) of Area Under the Curve (AUC) for the Baseline-Corrected Thickness of the Psoriatic Infiltrate0.03% E6201 Gel-763.195% Confidence Interval -1548.2 to 22.1um.day
Summary Statistics and Primary Pairwise Comparison (Vehicle-E6201) of Area Under the Curve (AUC) for the Baseline-Corrected Thickness of the Psoriatic Infiltrate0.05% E6201 Gel-1758.295% Confidence Interval -2134.3 to -1382.1um.day
Summary Statistics and Primary Pairwise Comparison (Vehicle-E6201) of Area Under the Curve (AUC) for the Baseline-Corrected Thickness of the Psoriatic Infiltrate0.1% E6201 Gel-904.495% Confidence Interval -1303.4 to -505.4um.day
Summary Statistics and Primary Pairwise Comparison (Vehicle-E6201) of Area Under the Curve (AUC) for the Baseline-Corrected Thickness of the Psoriatic Infiltrate0.2% E6201 Gel-920.895% Confidence Interval -1588.3 to -253.3um.day
Change in Thickness of the Psoriatic Infiltrate From Baseline to End of Treatment (Day 12/Discontinuation)Daivonex (Calcipotriene Cream)-205.395% Confidence Interval -239.2 to -171.4um
Change in Thickness of the Psoriatic Infiltrate From Baseline to End of Treatment (Day 12/Discontinuation)E6201 Vehicle7.195% Confidence Interval -32.2 to 46.3um
Change in Thickness of the Psoriatic Infiltrate From Baseline to End of Treatment (Day 12/Discontinuation)0.005% E6201 Gel-94.495% Confidence Interval -154.5 to -34.3um
Change in Thickness of the Psoriatic Infiltrate From Baseline to End of Treatment (Day 12/Discontinuation)0.01% E6201 Gel-175.395% Confidence Interval -206.5 to -144.1um
Change in Thickness of the Psoriatic Infiltrate From Baseline to End of Treatment (Day 12/Discontinuation)0.03% E6201 Gel-162.495% Confidence Interval -194.1 to -130.7um
Change in Thickness of the Psoriatic Infiltrate From Baseline to End of Treatment (Day 12/Discontinuation)0.05% E6201 Gel-239.595% Confidence Interval -295.8 to -183.2um
Change in Thickness of the Psoriatic Infiltrate From Baseline to End of Treatment (Day 12/Discontinuation)0.1% E6201 Gel-125.295% Confidence Interval -202.3 to -48.2um
Change in Thickness of the Psoriatic Infiltrate From Baseline to End of Treatment (Day 12/Discontinuation)0.2% E6201 Gel-137.995% Confidence Interval -218.3 to -57.6um
Change in Thickness of the Psoriatic Infiltrate From Baseline to Day 8Daivonex (Calcipotriene Cream)-151.795% Confidence Interval -215.1 to -88.3um
Change in Thickness of the Psoriatic Infiltrate From Baseline to Day 8E6201 Vehicle17.395% Confidence Interval -20.2 to 54.8um
Change in Thickness of the Psoriatic Infiltrate From Baseline to Day 80.005% E6201 Gel-63.495% Confidence Interval -110.3 to -16.5um
Change in Thickness of the Psoriatic Infiltrate From Baseline to Day 80.01% E6201 Gel-110.795% Confidence Interval -147.3 to -74.0um

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01268527/results

API referenceFor AI assistants